In the UK, a clinical testing of a vaccine that is not stored in a refrigerator

In the UK, the world’s first clinical testing of a vaccine, which does not need to be stored in a refrigerator, will increase, which would increase access to it, PA Media/DPA reported. Stablepharma’s tetanus and diphtheria (SPVX02) tetanus and diphtheria (SPVX02) is completely stable at room temperature and according to the company up to 60 other vaccines can benefit from modern technology.

The first testing of the vaccine on humans was held at the Clinical Research Center of the National Institute of Health and Care Institute (NIHR) at Southampton at the University Hospital in Southampton. The clinical trial is led by Sol Faust of the University of Southampton and Stablepharma CEO Karen O’hanon.

One of the biggest obstacles for people to vaccinate in some parts of the world is the « cold chain » needed to maintain vaccines cold from production until they are injected. The biotechnology company Stablepharma converts existing approved vaccines into « no refrigerator » versions, which can be stored for long periods of time at room temperature. This can save many lives worldwide by delivering vaccines to poorer countries.

The World Health Organization (WHO) estimates that half of the vaccines worldwide are wasting each year – to a large extent due to the lack of temperature control and difficult logistics required to maintain a continuous « cold chain ».

Stablepharma hopes that the new vaccine will begin to be used globally by 2027.